CGIM
VRDN icon

Cannon Global Investment Management’s Viridian Therapeutics VRDN Stock Holding History

Cannon Global Investment Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,600
Closed -$233K – 66
2022
Q1 		$233K Buy
+12,600
New +$242K 0.17% 87

Other funds holding VRDN

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cannon Global Investment Management's VRDN Position: Q2 2022 in Review

Cannon Global Investment Management sold out of Viridian Therapeutics (VRDN) in Q2 2022, closing a stake of 12,600 shares — an estimated $233K sold.

Cannon Global Investment Management first reported a position in VRDN in Q1 2022 and held it in 1 quarter. The position peaked at $233K in Q1 2022. 84 funds tracked by Wall St. Rank hold VRDN as of Q2 2022.

  • Cannon Global Investment Management reported no remaining Viridian Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Cannon Global Investment Management sold 12,600 Viridian Therapeutics shares in Q2 2022, an estimated $233K.
  • Cannon Global Investment Management first reported a position in Viridian Therapeutics in Q1 2022 and held it in 1 quarter.
  • Cannon Global Investment Management's Viridian Therapeutics position peaked at $233K in Q1 2022.
  • 84 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2022.

Based on Cannon Global Investment Management's 13F filing for Q2 2022, filed 4 Aug 2022.